





To: Keystone First and Keystone First Community HealthChoices (CHC) Providers

**Date: October 23, 2025** 

Re: Update: Formulary Changes

## The following products will have new or updated quantity limits.

Members/Participants currently receiving more than the quantity limit, whom it is not medically advisable to change therapy, will require prior authorization effective **January 1, 2026.** 

Formulary Limits		
Product List	Daily Quantity Limit	
Alyftrek Oral Tablet 4-20-50 MG	3 tablets per day	
Bimzelx Subcutaneous Solution Auto-injector 160 MG/ML	0.04 ML per day	
Gomekli Oral Capsule 1 MG	1.5 capsules per day	
Symbravo Oral Tablet 20-10 MG	0.24 MG per day	
Teriparatide Subcutaneous Solution Pen-injector 560 MCG/2.24ML	0.08 ML per day	

## Additional prior authorization criteria may apply. Please refer to most recent drug formulary and prior authorization information available on-line at:

<u>www.keystonefirstpa.com</u>  $\rightarrow$  *Pharmacy*  $\rightarrow$  *Pharmacy Homepage* <u>www.keystonefirstchc.com</u>  $\rightarrow$  *For Providers*  $\rightarrow$  *Pharmacy services* 

## If you have any questions regarding this notice, please contact Pharmacy Services:

if you have any questions regarding this notice, pieuse contact i harmacy services.	
Plan Name	Telephone Number
Keystone First	1-800-588-6767
Keystone First Community HealthChoices	1-866-907-7088

Coverage by Vista Health Plan, an independent licensee of the Blue Cross and Blue Shield Association.